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Abstract
Background: Previous studies established a possible link among hyperhomocysteinemia (HHcy), dyslipidemia, and
atherosclerosis. However, there was limited epidemic data concerning the relation between HHcy and lipid profiles,
especially in community-based Chinese populations. This study aim to investigate the association of plasma
homocysteine (Hcy) level with lipid profiles in a Chinese community-based population without lipid-lowering
treatment.
Method: A total of 4660 Chinese subjects from a cohort of the Shijingshan district in Beijing were included in the
analysis. Plasma total Hcy, serum lipid files including total cholesterol (TC), triglycerides (TG), low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) as well as relevant metabolic risk factors were
measured. Multivariate regression models adjusting for age, gender, smoking, drinking, physical activity, vitamin B
supplement, body mass index, fasting blood glucose level, serum creatinine, systolic and diastolic blood pressure
were used to evaluate associations of Hcy and lipid profiles.
Result: Subjects were 56.75 ± 8.91 years old, and 38.15% were male. Median (IQR) Hcy was 11.98 (10.00–14.93) μmol/L,
and 24.4% had HHcy (defined as Hcy≥ 15 μmol/L). Mean (SD) baseline TC was 5.34 ± 0.98 mmol/L, LDL-C was 3.27 ± 0.
81 mmol/L, and HDL-C was 1.43 ± 0.38 mmol/L. Median (IQR) of TG was 1.28 (0.91–1.85) mmol/L. In multivariable
linear-regression analyses, lnHcy (ln transformation for Hcy) level was positively associated with lnTG (adjusted β = 0.
075, SE = 0.021, P = 0.001). Using Hcy < 15 μmol/L as a reference, HHcy was independently associated with both lnTG
(adjusted β = 0.056, SE = 0.020, P = 0.004) and lnHDL (adjusted β = −0.018, SE = 0.009, P = 0.038). In multivariable logistic-
regression analyses, HHcy was associated with increasing risk of low HDL-C (HDL-C < 1.04 mmol/L; adjusted odds ratio
[OR] =1.406, 95% confidence interval [CI]: 1.143 – 1.728, P = 0.001) and hypertriglyceridemia (TG≥ 1.7 mmol/L; adjusted
OR = 1.293, 95% CI: 1.096–1.524, P = 0.002) after adjusting the confounders. However, there were no significant
associations between Hcy and TC or LDL-C.
Conclusion: The present study showed that HHcy was independently associated with hypertriglyceridemia and low
levels of HDL-C, which provides evidence that Hcy levels might affect HDL-C and TG metabolism.
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Background
Hyperhomocysteinemia (HHcy) has been regarded as a
new modifiable risk factor for cardiovascular disease
(CVD) through various mechanisms, including vascular
endothelium damage, stimulation of smooth muscle cell
proliferation, enhanced low-density lipoprotein cholesterol
(LDL-C) peroxidation and thrombosis activation [1, 2].
Previous studies also established that there was a possible
link among HHcy, dyslipidemia and atherosclerosis.
Regarding Hcy, an inverse association between this
amino acid and lipoproteins, especially high-density
lipoprotein cholesterol (HDL-C), has been well
described in humans and various animal models of
HHcy [3]. HHcy might also increase the risk of CVD
in dyslipidemia patients [4–6]. Although the mechanism
of the link is not thoroughly known, recent studies
strongly demonstrated the importance of the meta-
bolic balance between S-adenosylmethionine (SAM),
S-adenosylhomocysteine (SAH), phosphatidylcholine
(PC), phosphatidylethanolamine (PE) and choline in
Hcy metabolism, hypolipoproteinemia, liver function,
and CVD [3, 7]. Several studies relating HHcy to
disturbed HDL-C metabolism showed that Hcy can
reduce circulating HDL-C via inhibiting ApoA-I pro-
tein synthesis and enhance HDL-C clearance [8, 9].
However, there are limited epidemic data about the
relationship between HHcy and lipid profiles, espe-
cially in community-based Chinese populations. This
study aims to investigate the association of plasma
Hcy level with lipid profiles in a Chinese community-
based population without lipid-lowering treatment.
Methods
Subject
Participants were from an atherosclerosis cohort survey
performed in the Gucheng and Pingguoyuan communities
of the Shijingshan district in Beijing, China from
December 2011 to April 2012. The methods and primary
results of this survey have been reported elsewhere [10]. A
total of 4,660 eligible participants aged 40 years old and
above were included in this analysis, after excluding those
with missing covariates and those under lipid-lowering
treatment. The proposal was approved by the ethics com-
mittee of both Peking University and Peking University
First Hospital, and all subjects signed informed consent
before enrollment.
Data collection
Baseline data were collected by trained research staff
according to a standard operating procedure. Each par-
ticipant was interviewed using a standardized question-
naire designed specifically for the present study that
provided information related to education status, med-
ical history, body mass index (BMI), past and current
medication use, and personal habits such as use of
vitamin B (VB) supplements and exercise habits, as well
as cigarette and alcohol consumption. Seated brachial
blood pressure (BP) and pulse for each participant were
obtained by trained researchers after subjects rested for
5 min; an Omron HEM-7117 electronic sphygmoman-
ometer was used. The mean of three consecutive mea-
surements was used in the analysis.
Blood sample collection and laboratory methods
After an overnight fast of at least 12 h, a venous blood sam-
ple was obtained from the forearm of each participant.
Plasma samples were separated within 30 min of collection
and were stored at −80 °C. Plasma Hcy was measured using
an electrochemiluminescence method at Southern Medical
University Nanfang Hospital National Clinical Research
Center for Kidney Disease in Guangzhou. Serum total chol-
esterol (TC), LDL-C, HDL-C, triglycerides (TG), fasting
blood glucose (FBG), and creatinine (Scr) at baseline were
measured on a Roche C8000 Automatic Analyzer in the la-
boratory of Chinese PLA General Hospital. According to
the China Adult Dyslipidemia Prevention Guide (2007
Edition) criteria [11], we defined TC ≥5.18 mmol/L as
hypercholesterolemia, LDL-C ≥3.37 mmol/L as a high level
of LDL-C, HDL-C <1.04 mmol/L as low HDL-C, and TG
≥1.7 mmol/L as hypertriglyceridemia. According to results
from previous studies [12], Hcy ≥ 15 μmol/L is often de-
fined as HHcy. Additionally, in the present study,
15 μmol/L was the cut-off value of the upper quartiles of
Hcy, so we defined Hcy ≥ 15 μmol/L as HHcy and divided
the participants into two groups (Hcy ≥ 15 μmol/L and
Hcy < 15 μmol/L) for further analysis.
Statistical analysis
Categorical variables are expressed as numbers and
percentages. Continuous variables are described using
means with standard deviations for data with normal
distribution, and medians with interquartile range (IQR)
for non-normally distributed data. According to Hcy
level, the participants were stratified into Hcy quartiles
or two groups with cut-off value of 15 μmol/L. Univariate
comparison was made between groups using the ANOVA
test, and the χ2 test for categorical variables. The trend
test (univariate analysis of each variate with Hcy quartiles)
was used to test the linear trend of covariates with
the increasing of Hcy. Multiple linear and logistic re-
gression analysis adjusted for age, gender, smoking,
alcohol drinking, VB supplement, BMI, FBG, pulse,
physical activity, education level, BP and Scr was per-
formed to assess the associations between each lipid
profile and Hcy. All analyses were conducted using
Empower(R) (www.empowerstats.com, X&Y solutions,
inc. Boston MA). A P-value <0.05 was considered statisti-
cally significant.
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Results
Subjects were 56.75 ± 8.91 years old, and 38.15% were
male. The median (IQR) value of Hcy was 11.98 (10.00 –
14.93) μmol/L, and 24.4% of subjects had HHcy. In order
to have an even distribution in each group, the subjects
were divided into subgroups using Hcy quartiles (Q1:
4.66–9.99 μmol/L; Q2: 10.00–11.97 μmol/L; Q3: 11.98–
14.92 μmol/L; and Q4: 14.93–141.47 μmol/L). The trend
test showed that with higher Hcy grade, subjects were
older, more males, more smokers and drinkers. Also,
levels of TG, Scr, BP, pulse, BMI and the proportion of
physically active subjects were significantly higher. In con-
trast, with increased Hcy grade, HDL-C level, education
level and the proportion of patients who took VB supple-
ments were lower. No differences were observed for FBG.
These data are presented in Table 1.
Multivariable regression analysis was carried out to
assess whether Hcy was independently associated with
these lipid profiles by adjusting for likely confounders.
Model 1 was univariate analysis, Model 2 adjusted age
and gender, model 3 adjusted age, gender, smoking,
alcohol drinking, VB supplement, BMI, FBG, pulse,
physical activity, education level, BP and Scr. In multi-
variable linear-regression analyses, lnHcy was positively
associated with the lnTG in both models (adjusted β in
full model = 0.075, SE = 0.021, P = 0.001). lnHcy was
negatively associated with lnHDL (β = −0.024, SE = 0.010,
P = 0.021) after adjustment for age and sex, but the associ-
ation turned statistically insignificant after adjustment for
all confounders (β = −0.016, SE = 0.010, P = 0.115).
Though similar inverse trends were seen for lnTC
and lnLDL, these were not statistically significant.
When Hcy <15 μmol/L group was used as the reference,
Hcy ≥ 15 μmol/L group was independently associated
with lnTG (adjusted β in full model = 0.056, SE =
0.020, P = 0.004) and lnHDL (adjusted β in full
model = −0.018, SE = 0.009, P = 0.038) as well. No
positive associations were observed between HHcy and
lnTC or lnLDL-C. These data are presented in Table 2.
Furthermore, HHcy was associated with increasing
risk of low HDL-C (adjusted odds ratio [OR] in full
model = 1.406, 95% confidence interval [CI]:1.143–1.728,
P = 0.001) and hypertriglyceridemia (adjusted OR in full
model = 1.293, 95% CI: 1.096–1.524, P = 0.002) in multi-
variable logistic-regression analyses. Similar significant
findings were also found when analyzed the relation be-
tween InHcy and low HDL-C and hypertriglyceridemia.
However, there were no significant correlations between
HHcy and hypercholesterolemia or high LDL-C. These
data are presented in Table 3.
Discussion
The major findings of the present study are that HHcy
status is independently associated with lower HDL-C
and higher TG. The population of the present study was
from a Chinese urban community. Compared to prior
studies based on Chinese population, the lipid levels
observed in this population are close to those reported
in recent epidemic data [13–15]. The median level of
Hcy was 11.98 μmol/L, which is comparable to other
data [12].
The interaction between lipids and Hcy metabolism
has been tested in several animal models for HHcy,
hypercholesterolemia, or both [16–20]. There are also
some invaluable clinical observations that demonstrate
the possible link between Hcy and lipid metabolism
pathways. Durdi et al. reported that in 126 myocardial
infarction patients, Hcy was significantly and negatively
correlated with HDL-C (P < 0.05, r = −0.93) and there
was also a positive correlation between total Hcy and
LDL-C (P < 0.05, r = 0.98) [21]. In 300 Indian subjects
with proven coronary heart disease, Hcy was found to be
positively associated with TG and VLDL-C, and negatively
with HDL-C [22]. In 125 heterozygous familial hyperchol-
esterolemia patients, Hcy (r = −0.370, P = 0.003) and
methylenetetrahydrofolate reductase (MTHFR) TT geno-
type were associated with low HDL values [23]. Anan et
al. reported similar results to those observed during the
present study that Hcy is associated with TG and HDL-C,
but not with TC nor LDL-C in 40 Japanese patients with
diabetes [24], Rosa et al. reported that Hcy correlates
negatively with ApoA-I and with HDL-C in elderly rural
subjects from Sicily [25]. Focusing on Chinese subjects, in
2058 Chinese consecutive coronary artery angiographic
patients, Hcy was found to be negatively correlated with
HDL-C (r = −0.148, P < 0.001) [4]. In northern Chinese
subjects, the prevalence of HHcy in the combined hyper-
lipidemia (high TG combined highTG) group has been re-
ported to be significantly higher than that in the control
with an OR of 3.339 [26]. However, not all prior studies
have found correlations between HHcy and lipid profiles.
Yadav reported that there was no significant correlation
between plasma Hcy and TC, HDL-C, and TG in 60 is-
chemic heart disease patients [27]. A study that enrolled
155 diabetes patients and found no significant association
between Hcy and lipids either [28]. Importantly, most re-
cent data including 18297 US adults from the Vary Large
Database of Lipids indicate that, in unadjusted analysis,
levels of LDL-C, non-HDL-C and HDL-C were lower
whereas levels of TG and VLDL-C were higher in the
highest Hcy quartile, but after adjusting confounders the
associations disappeared [29]. Compared to the results
from the present study, the VLDL-21 study included a
general population with similar age, sex ratio, and the Hcy
level. However, the lipid levels were much lower than
those observed in the present study. Also, information of
lipid-lowering medication, one of the most confounders,
was uncertain in VLDL-21 study. In a multiple linear
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regression model, only age, sex, HbA1c, insulin and Scr
were adjusted. Other factors such as BMI, statin usuage,
VB supplement, drinking status, and physical activities
weren’t taken into account, which should partly explain
the discrepancy between two studies.
In summary, while studies examining the association
between HHcy and lipid profiles in humans have had
mixed conclusions, the most consistent findings indicate
that higher Hcy is associated with decreased serum
HDL-C and increased TG, which are consistent with the
results of the present study. Furthermore, we found that
TC and LDL-C levels showed a downward trend in the
HHcy group, but there is no significant difference. The
clinical and epidemical data concerning correlations be-
tween Hcy and TC, LDL-C are very limited, indicating
that more studies are needed. To the best of our know-
ledge, this was the largest study in Chinese population
which could provide enough statistical power to evaluate
the association of Hcy and lipid profiles. Besides, most
prior researches were aimed at CVD patients or high
risk patients, therefore, there is little reliable data about
this phenomenon in community-based population. The
population in the present study is community-based,
which could provide more evidence for extrapolating the
Table 1 Baseline Characteristics Stratefied by Hcy quartiles











N 4660 1161 1169 1161 1169
Age (year-old), mean ± SD 56.75 ± 8.91 53.31 ± 7.41 56.28 ± 7.97 58.59 ± 9.21 58.82 ± 9.72 <0.001 <0.001
Sex, N (%)
Male 1778 (38.15%) 117 (10.08%) 319 (27.29%) 533 (45.91%) 809 (69.20%) <0.001 <0.001
Female 2882 (61.85%) 1044 (89.92%) 850 (72.71%) 628 (54.09%) 360 (30.80%)
Scr (μmol/L), mean ± SD 59.44 ± 14.23 57.22 ± 9.05 63.25 ± 11.66 69.08 ± 13.44 77.34 ± 17.78 <0.001 <0.001
TC (mmol/L), mean ± SD 5.34 ± 0.98 5.37 ± 0.99 5.40 ± 0.91 5.35 ± 0.97 5.23 ± 1.03 <0.001 <0.001
TG (mmol/L), Median (IQR) 1.28 (0.91–1.85) 1.24 (0.88–1.84) 1.25 (0.90–1.73) 1.28 (0.94–1.81) 1.35 (0.95–2.01) <0.001 <0.001
HDL-C (mmol/L), mean ± SD 1.43 ± 0.38 1.49 ± 0.36 1.47 ± 0.36 1.43 ± 0.38 1.36 ± 0.39 <0.001 <0.001
LDL-C (mmol/L), mean ± SD 3.27 ± 0.81 3.28 ± 0.81 3.32 ± 0.77 3.30 ± 0.81 3.19 ± 0.85 <0.001 0.011
FBG (mmol/L), mean ± SD 6.16 ± 1.80 6.12 ± 1.80 6.20 ± 1.91 6.20 ± 1.85 6.10 ± 1.62 0.389 0.728
BMI (Kg/m2), mean ± SD 26.00 ± 3.37 25.86 ± 3.54 25.92 ± 3.31 26.07 ± 3.36 26.1 ± 3.28 0.130 0.019
SBP (mmHg), mean ± SD 133.89 ± 16.85 130.91 ± 16.34 132.90 ± 16.49 135.07 ± 16.91 136.65 ± 17.12 <0.001 <0.001
DBP (mmHg), mean ± SD 75.21 ± 9.95 74.48 ± 9.48 75.07 ± 9.85 74.85 ± 9.86 76.42 ± 10.47 <0.001 <0.001
Pulse (bpm), mean ± SD 78.51 ± 11.41 78.15 ± 10.36 78.25 ± 11.20 78.50 ± 11.61 79.13 ± 12.35 0.159 0.033
Education level, N (%)
Elementary above 4581 (98.30%) 1150 (99.05%) 1153 (98.63%) 1137 (97.93%) 1141 (97.60%) 0.029 0.003
Illiterate 79 (1.70%) 11 (0.95%) 16 (1.37%) 24 (2.07%) 28 (2.40%)
Smoking status, N (%)
Current and former 1249 (26.80%) 96 (8.27%) 230 (19.67%) 356 (30.66%) 567 (48.50%) <0.001 <0.001
Never 3411 (73.20%) 1065 (91.73%) 939 (80.33%) 805 (69.34%) 602 (51.50%)
Alcohol drinking, N (%)
Current and former 1204 (25.84%) 136 (11.71%) 242 (20.70%) 319 (27.48%) 507 (43.37%) <0.001 <0.001
Never 3456 (74.16%) 1025 (88.29%) 927 (79.30%) 842 (72.52%) 662 (56.63%)
Physical activity, N (%)
Once a week above 3737 (80.43%) 896 (77.24%) 928 (79.66%) 971 (83.85%) 942 (80.79%) <0.001 0.005
Others 912 (19.57%) 264 (22.76%) 237 (20.34%) 187 (16.15%) 224 (19.21%)
Vitamin B supplement, N (%)
Once a week above 386 (8.28%) 137 (11.80%) 105 (9.01%) 77 (6.64%) 67 (5.74%) <0.001 <0.001
Others 4269 (91.72%) 1024 (88.20%) 1061 (90.99%) 1083 (93.36%) 1101 (94.26%)
Abbreviations: TC Total cholesterol, TG Triglycerides, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hcy Homocysteine,
Scr Serum creatinine, BMI Body mass index, FBG Fasting blood glucose, SBP Systolic blood pressure, DBP Diastolic blood pressure, IQR Interquartile range
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Table 2 Multivariate linear regression for effects of Hcy on lipid profiles
Model 1 Model 2 Model 3
β (SE) P β (SE) P β (SE) P
LnTG (mmol/L)
LnHcy 0.102 (0.020) <0.001 0.077 (0.022) <0.001 0.075 (0.021) 0.001
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L 0.084 (0.018) <0.001 0.061 (0.020) 0.001 0.056 (0.020) 0.004
LnHDL-C (mmol/L)
LnHcy −0.098 (0.010) <0.001 −0.024 (0.010) 0.021 −0.016 (0.010) 0.115
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L −0.082 (0.009) <0.001 −0.026 (0.010) 0.003 −0.018 (0.009) 0.038
LnTC (mmol/L)
LnHcy −0.033 (0.007) <0.001 −0.002 (0.008) 0.739 −0.002 (0.008) 0.771
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L −0.029 (0.006) <0.001 −0.005 (0.006) 0.486 −0.006 (0.007) 0.691
LnLDL-C (mmol/L)
LnHcy −0.044 (0.010) <0.001 −0.016 (0.011) 0.095 −0.018 (0.012) 0.133
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L −0.039 (0.009) <0.001 −0.017 (0.009) 0.080 −0.017 (0.010) 0.071
Model 1 univariate analysis
Model 2 adjusted for age and sex
Model 3 adjusted for age, sex, education level, physical activity, vitamin B supplement, body mass index, pulse, fasting glucose, smoking status, drinking status,
systolic blood pressure, diastolic blood pressure, serum creatinine
Abbreviations: TC Total cholesterol, TG Triglycerides, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hcy Homocysteine
Table 3 Multivariate Logistic Regression for Effects of Hcy on Dyslipidemia
Model 1 Model 2 Model 3
OR (95% CI) P OR (95% CI) P OR (95% CI) P
TG≥ 1.70 (mmol/L)
LnHcy 1.391 (1.192, 1.623) <0.001 1.327 (1.117, 1.576) 0.001 1.267 (1.051, 1.525) 0.013
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L 1.377 (1.195, 1.586) <0.001 1.324 (1.136, 1.544) <0.001 1.293 (1.096, 1.524) 0.002
HDL-C <1.04 (mmol/L)
LnHcy 2.167 (1.797, 2.614) <0.001 1.301 (1.049, 1.614) 0.017 1.277 (1.013, 1.613) 0.039
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L 2.114 (1.769, 2.526) <0.001 1.401 (1.154, 1.701) <0.001 1.406 (1.143, 1.728) 0.001
TC≥ 5.18 (mmol/L)
LnHcy 0.746 (0.645, 0.864) <0.001 0.991 (0.840, 1.168) 0.910 0.950 (0.798, 1.130) 0.562
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L 0.754 (0.660, 0.862) <0.001 0.930 (0.804, 1.075) 0.326 0.908 (0.779, 1.057) 0.214
LDL-C≥ 3.37 (mmol/L)
LnHcy 0.770 (0.662, 0.894) <0.001 0.906 (0.766, 1.072) 0.250 0.904 (0.757, 1.080) 0.265
Hcy < 15 μmol/L Ref. - Ref. - Ref. -
Hcy≥ 15 μmol/L 0.716 (0.624, 0.821) <0.001 0.869 (0.750, 1.007) 0.061 0.910 (0.774, 1.071) 0.256
Model 1 univariate analysis
Model 2 adjusted for age and sex
Model 3 adjusted for age, sex, education level, physical activity, vitamin B supplement, body mass index, pulse, fasting glucose, smoking status, drinking status,
systolic blood pressure, diastolic blood pressure, serum creatinine
Abbreviations: TC Total cholesterol, TG Triglycerides, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hcy Homocysteine
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results to the general population. Additionally, most
prior studies conducted univariate analysis or multivari-
ate analysis adjusting for few confounders. Our study
not only excluded subjects with lipid-lowering drugs
which is one of the most important confounders, but
also included many additional coviarates such as FBG,
BMI, kidney function, physical activity, among others.
There are many experimental foundations that provide
support for the hypothesis that Hcy affects lipid metab-
olism. (1) Prior study results suggest the mechanisms for
HHcy are mainly related to the down regulation of key
players in HDL production (Apo-AI, lecithin-cholesterol
acyltransferase (LCAT)) [30] and the reducing of the
liver Apo-AI mRNA expression [31]. (2) The inhibition
of PC conversion to PE and the low ratio of PE/PC
caused by HHcy are key issues in the relationship be-
tween HHcy and triglycerides accumulation [32, 33].(3)
Hcy has been found to enhance the expression of sterol
regulatory element-binding proteins (SREBPs) to increase
intracellular accumulation of TC and TG [34]. (4) Hcy
causes protein misfolding in the endoplasmic reticulum
and oxidative stress, which might affect lipoprotein par-
ticle production [34–38]. (5) Global DNA hypomethyla-
tion has been suggested as a mechanism linking Hcy to
lipid disorders and atherosclerosis in vascular smooth
muscle cells [39]. (6) Plasma concentrations of TG have
significantly important effects on the distribution of HDL
subclasses, and HDL maturation might be abnormal and
reverse cholesterol transport might be weakened in HTG
patients [40]. Consequently, the findings in the present
study might partially be explained by the interaction be-
tween TG and HDL-C.
The present study also has several limitations. It was a
cross-sectional study, thus predictions about the incidence
of dyslipidemia due to HHcy in the community-based
population cannot be made from this study. Additionally,
serum lipid profiles might relate to dietary habits that
were not assessed in detail due to lack of such data. Fur-
ther follow-up data in this cohort as well as independent
replication are needed.
Conclusion
The present study showed that HHcy status is indepen-
dently associated with hypertriglyceridemia and low HDL-
C levels, which provides evidence that Hcy might affect
HDL-C and TG metabolism.
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